An equity financing round targeted at $19 million has pulled in $14 million for NeuWave Medical, a spinoff of the University of Wisconsin-Madison. The company is the maker of the Certus 140 soft-tissue ablation system, which is used primarily to aid in the treatment of kidney, liver and lung tumors.

Related Summaries